breast-cancer-summit-2017-scientifictracks-abstracts

11 / 12

Page 35
Notes:
conferenceseries.com
Volume 2, Issue 2 (Suppl) Breast Can Curr Res
ISSN: 2572-4118 BCCR, an open access journal Breast Cancer Summit 2017
May 08-10, 2017
May 08-10, 2017 Singapore
4th World Congress on
Breast Cancer
Thymoquinone inhibits bone metastasis of triple negative breast cancer cells through the suppression of
CXCR4 signaling axis
Muthu K Shanmugam, Annie Hsu, Gautam Sethi and Benny K H Tan
National University of Singapore, Singapore
Several lines of evidence(s) indicate that CXCR4 overexpression has been correlated with distant site metastasis and poor overall
survival rate in patient with breast cancer. The tumor metastasis promoting molecule CXCR4 is considered as a potential therapeutic
target for inhibiting breast cancer metastasis. Thus, novel agents that can down-regulate CXCR4 expression have potential against breast
cancer metastasis. In the present report we investigated the effect of thymoquinone (TQ), derived from the seeds of medicinal plant
Nigella sativa, on the expression and regulation of CXCR4 in breast cancer cells. In addition, we evaluated the effect of TQ in a metastasis
mouse model established by intracardiac injection of luciferase-tagged MDA-MB-231 breast cancer cells that metastasize to the bones.
We observed that TQ could inhibit the expression of CXCR4 in MCF-7 and MDA-MB-231 cells in a dose and time dependent manner.
TQ (2 mg/kg or 4 mg/kg) treatment for four weeks significantly inhibited tumor growth and significantly reduced metastases to multiple
vital organs, including lungs, brain and bone. Immuno-histochemical analysis of the lung and brain tissue showed significant reduction
in the expression of CXCR4, Ki67, MMP9, VEGFR2 and COX2 compared to tissues from control mice. TQ treatment also reduced
the overall bone tumor burden. Overall, our results show that TQ exerts its antitumor and anti-metastatic effects by downregulation of
CXCR4 expression both in vitro and in vivo thus may have possible potential for the treatment of breast cancer.
Acknowledgement: This work was supported by NUHS Basic Seed Research grant to Prof. Benny Tan.
Biography
Muthu K Shanmugam is a senior research fellow in the Department of Pharmacology, National University of Singapore, Yong Loo Lin School of Medicine. He got his
Ph.D in cancer pharmacology and he is currently working as a senior research fellow. He has twelve years of experience in experimental laboratory research and
have published in journal papers and presented at international conferences. Muthu K Shanmugam has vast experience in cancer biology, inflammatory diseases,
orthotopic, xenograft and transgenic mice models, in molecular biology, cell and tissue culture experiments. In addition, he is trained in high-throughput technology
such as cDNA microarray technology, antigen and antibody array technology, two dimensional gel electrophoresis, mass spectrometry, pharmacokinetics and in
the development of array based clinical diagnostic tools.
Muthu K Shanmugam et al., Breast Can Curr Res 2017, 2:2(Suppl)